Eisai

Diversified pharma, neurology franchise

4523 · TSE · Japan

Public Market Listing

4523TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Eisai are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(18 total)
18Total Assets
10Approved
3Phase 3 / Filed
5Phase 1–2 / Early
15Diseases
Quick filter:
Showing 18 of 18 assets
Target & Modality
Approved
AcetylcholinesteraseSmall molecule
Alzheimer's Disease
entacapone(Comtess)
Approved
COMTSmall molecule
Parkinson's Disease
Approved
Tubulin / microtubulesSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Lecanemab(Leqembi)
Approved
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
Perampanel(Fycompa)
Approved
AMPA receptor (antagonist)Small molecule
Epilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures
Rabeprazole(Aciphex)
Approved
H+/K+-ATPase (gastric proton pump)Small molecule
Helicobacter pylori Infection
Approved
CGRP receptorSmall molecule
Migraine
Approved
Voltage-gated sodium channelSmall molecule
EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer
Approved
Voltage-gated sodium channelsSmall molecule
Epilepsy
Phase 3
NF-kB
Rheumatoid Arthritis
Mitiglinide(Glufast)
Phase 3
SUR1 (short-acting)Small molecule
Type 2 Diabetes
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer
Phase 2/3
Tau (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
Lemborexant(Dayvigo)
Phase 2
Orexin receptor (repositioned)Small molecule
Alzheimer's Disease

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Rimegepant (Nurtec ODT)Phase 3Menstrual Migraine
Est. primary completion 2026-11-29 · NCT06641466 · CT.gov ↗
What to watch
December 2026 (2)
Lecanemab · Leqembi + EtalanetugPhase 2Alzheimer's Disease
Est. primary completion 2026-12-03 · NCT06602258 · CT.gov ↗
What to watch
Lecanemab · LeqembiPhase 3Early Alzheimer's Disease
Est. primary completion 2026-12-31 · NCT03887455 · CT.gov ↗
What to watch
2027 (7)
March 2027 (2)
stenoparibPhase 2Advanced Ovarian Cancer
Est. primary completion 2027-03 · NCT03878849 · CT.gov ↗
What to watch
Eribulin mesylatePhase 1/2Solid Neoplasms
Est. primary completion 2027-03-31 · NCT04078295 · CT.gov ↗
What to watch
April 2027 (1)
Perampanel · FycompaPhase 2Pediatric Epileptic Syndrome, Partial-onset Seizures
Est. primary completion 2027-04-06 · NCT04015141 · CT.gov ↗
What to watch
May 2027 (1)
SerplulimabPhase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
June 2027 (1)
SerplulimabPhase 2Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
July 2027 (1)
SerplulimabPhase 1/2Colon Cancer Adenocarcinoma
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
December 2027 (1)
SerplulimabPhase 2Carcinoma of Head and/or Neck
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
2028 (2)
October 2028 (1)
Rimegepant (Nurtec ODT)Phase 3Preventive Treatment of Migraine
Est. primary completion 2028-10-21 · NCT07729462 · CT.gov ↗
What to watch
December 2028 (1)
Lecanemab · LeqembiPhase 3Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Est. primary completion 2028-12-21 · NCT04468659 · CT.gov ↗
What to watch
2029 (3)
January 2029 (2)
TaletrectinibPhase 3Non Small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06564324 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT)Phase 3Pediatric Migraine
Est. primary completion 2029-01-09 · NCT04649242 · CT.gov ↗
What to watch
March 2029 (1)
Est. primary completion 2029-03-27 · NCT05156398 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Est. primary completion 2030-02-26 · NCT06616194 · CT.gov ↗
What to watch
July 2030 (1)
Rimegepant (Nurtec ODT)Phase 3Acute Treatment of Migraine
Est. primary completion 2030-07-31 · NCT04743141 · CT.gov ↗
What to watch
August 2030 (1)
TaletrectinibPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-08-30 · NCT07154706 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
SerplulimabPhase 2/3Squamous NSCLC
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(26)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

4 January 2027FDA action dateTaletrectinibFDA target action date for IBTROZI sNDA
US, FDA · Source ↗

Recent

4 October 2026FDA action dateLenvatinibFDA PDUFA date for LENVIMA plus WELIREG in RCC
US, FDA · Source ↗
16 September 2026ApprovalTaletrectinibFDA approves IBTROZI supplemental application with updated duration of response
US, FDA · Nuvation Bio Inc. · Source ↗
3 September 2026ApprovalLecanemabNMPA approves Leqembi subcutaneous formulation as initiation treatment in China
CN, NMPA · Source ↗
September 2026ApprovalLecanemabJapan approves the LEQEMBI Pen subcutaneous formulation
JP, MHLW/PMDA · Eisai · Source ↗
24 August 2026FDA action dateLecanemabFDA extends PDUFA date for LEQEMBI IQLIK starting dose sBLA to August 24, 2026
US, FDA · Source ↗
16 July 2026Filing acceptedLemborexantEMA accepts the lemborexant marketing authorisation application for evaluation
EU, EMA · Eisai · Source ↗
13 July 2026ApprovalLecanemabFDA approves LEQEMBI IQLIK subcutaneous initiation dose in early Alzheimer's
US, FDA · Source ↗
2 July 2026Filing acceptedLemborexantMHRA accepts the lemborexant marketing authorisation application for evaluation
UK, MHRA · Eisai · Source ↗
29 June 2026Filing acceptedTaletrectinibUK MHRA validates taletrectinib MAA
UK, MHRA · Source ↗
June 2026Filing acceptedTaletrectinibMHRA validates taletrectinib marketing authorisation application
UK, MHRA · Nuvation Bio Inc. and Eisai · Source ↗
24 May 2026FDA action dateLecanemabPDUFA action date set for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
6 May 2026Filing acceptedTaletrectinibFDA accepts sNDA for IBTROZI with updated duration of response data
US, FDA · Source ↗

The 12 most recent of 25 past events are shown.

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$5.4B$1.0B$1.5B—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.2B$1.1B$1.8B—report ↗
2023-FY$5.1B———report ↗
2022-FY$5.5B———report ↗